A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system

Overview of attention for article published in Frontiers in Pharmacology, August 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

So far, Altmetric has seen 1 X post from an account with 452 followers.

Sotorasib and adagrasib show distinct safety profiles in NSCLC patients with KRAS G12C mutation. Notable risks include liver and renal issues—crucial info for clinicians managing treatment!🧬💊 Read more 👇 #LungCancer #Oncology #KRAS #Pharmacovigilance http

28 Aug 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.